HMGCS2を標的とする:ケトゲネシス抑制はT2DM併発性におけるNAFLDの進行を加速し,シナロシドはT2DM併発性におけるNASHを改善する
Yongsheng Shu1, Wanqing Shen1, Wanyu Feng1
1Department of Pharmacology, School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
Biomolecules
|August 28, 2025
まとめ
2型糖尿病における非アルコール性脂肪肝疾患 (NAFLD) を悪化させる. シナロシドによるケトゲネシスの強化は,この複雑な状態に対する治療戦略です.
科学分野:
- ヘパトロジー
- 内分泌学
- 代謝 疾患
背景:
- 非アルコール性脂肪肝 (NAFLD) と2型糖尿病 (T2DM) の併発は肝損傷を加速し,肝硬変と癌のリスクを高めます.
- ケトン体の生成であるケトゲネシスは代謝の調節に作用し,T2DMに関連したNAFLDでは変化することがあります.
研究 の 目的:
- T2DM媒介性NAFLDの悪化におけるケトゲネシスの役割を調査する.
- 非アルコール性脂肪肝炎 (NASH) によるT2DMにおけるシナロシドの治療メカニズムを解明する.
主な方法:
- CDAHFDとストレプトゾトシンを使ったマウスのT2DMモデルでNAFLDが確立された.
- 過剰表現またはノックダウンのためにアデノウイルスベクトル経由で調節された肝臓のHMGCS2発現
- シナロシドを経口投与し,肝臓病理,ケトゲネシス,老化マーカーを分析した.
主要な成果:
- T2DMはNAFLDの進行を加速し,ケトゲネシスと肝臓のHMGCS2発現の制御障害に関連しています.
- HMGCS2過剰発現は,ケトゲネシスを強化することによって,NASH- T2DMモデルにおけるステアト肝炎を弱めた.
- シナロシドは肝臓の損傷を緩和し,脂質の蓄積を減少させ,肝細胞老化とSASP因子を抑制しました.
結論:
- HMGCS2媒介によるケトゲン系不調は,T2DMにおけるNAFLDの病原化に寄与する.
- シナロシドは,HMGCS2媒介のケトゲネシスにより,NASH- T2DMにおいて治療効果を発揮する.
- ケトゲン調節はT2DM-NAFLDの進行を遅らせるための有望な治療戦略です.
関連する概念動画
Overview of Carbohydrate Metabolism
1.7K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.7K
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256


